Touting what’s been so far the “cleanest safety profile that’s been presented with genetic medicine in the eye,” deemed “a game changer for this field,” 4D Molecular Therapeutics Inc. CEO David Kirn ...

Wednesday, 4D Molecular Therapeutics, Inc.(NASDAQ:FDMT) unveiled interim 24-week data from the Population Extension cohort of its PRISM Phase 2 Clinical Trial. The trial evaluates intravitreal 4D ...

4D Molecular Therapeutics (NASDAQ:FDMT) shares surged over 60% premarket after the company reported positive interim data for its eye disease drug, 4D-150. Data consists of 24-week results from a ...

4D Molecular Therapeutics Inc (NASDAQ: FDMT) announced updated interim safety and efficacy data from the two 4D-310 INGLAXA Phase 1/2 trials for Fabry disease cardiomyopathy.

4D Molecular Therapeutics (NASDAQ:FDMT) has plunged 31% in Thursday morning trading following the release of interim phase 1/2 data on wet age-related macular degeneration (AMD) asset 4D-150.